Paid clinical trial for healthy volunteers aged 18 to 40.

Receive a payment for your time!

We are carrying out a clinical trial with a drug known as oxycodone. Oxycodone is a pain killer and has been used for the treatment of moderate to severe pain and post-operative pain. In Europe, oxycodone has been marketed as prolonged release tablets, which means it delivers the medication over an extended period of time. In the United States (US), oxycodone has been marketed as extended release tablets, which are also tamper resistant (i.e. cannot be deliberately altered). The aim of this study is to show that the oxycodone marketed in US works in the same way as the oxycodone which is marketed in the EU (i.e. bioequivalence).

Healthy males and females wanted for clinical trials
Register your interest in this clinical trial

Study summary

This study will be conducted at our clinical trials unit in London Bridge and will involve healthy volunteers. You will need to attend a screening appointment within 21 days of admission. If successful, you will be required to be in our unit for 2 in-house stays of 3 days/2 nights each and 1 follow-up visit 7 to 10 days after receiving the last dose.

Study dates

Cohort 3a

Period 1

  • Screening period: June 09th – July 24th 2018 (only 1x screening appointment required)
  • In-house period: July 25th – July 27th 2018

Period 2

  • In-house period: August 2nd  – August 4th 2018
  • Follow-up visit: Thursday 09th August 2018

Cohort 3b

Period 1

  • Screening period: June 16th – July 27th 2018 (only 1x screening appointment required)
  • In-house period: July 30th – August 1st 2018

Period 2

  • In-house period: August 6th  – August 8th 2018
  • Follow-up visit: Monday 13th August 2018


Who can take part?

To be eligible to take part in this study you must fit the following criteria

  • Healthy males or females aged between 18 and 40 (inclusive)
  • You must weigh between 50.0-100.0 kg (inclusive) and have a Body Mass Index (BMI) within the range 18.5-30.0 kg/m² (inclusive)
  • You must not have a history of smoking 45 days before you receive the study drug
  • You must not consume tobacco in any form or other nicotine-containing products 7 days before you receive the study drug
  • You must not test positive for hepatitis B/C, HIV, alcohol or drugs or show any evidence of drug or alcohol abuse within the last 12 months. (Alcohol abuse is defined as a regular weekly intake of more than 14 units)
  • You must be healthy with no underlying medical conditions that may either interfere with participation in the clinical study, and/or put you at any significant risk
  • You must not be on any regular medications, including over the counter medications
  • You must not have donated blood within 90 days prior to first dosing
  • You must not have any history of heart-related diseases or abnormalities that show up on your ECGs
  • You must not be pregnant or breastfeeding
  • Female volunteers of childbearing potential, if heterosexually active, must agree to the use of highly effective contraception starting at least one menstrual cycle before the drug administration.
  • Male volunteers must be willing to use appropriate contraception throughout the study and for at least 30 days after the last dose of study medication.

A full list of acceptable contraceptive methods will be discussed in full by a member of the recruitment team and a study doctor during screening.

Study payment

In recognition of the time involved in taking part in this study, you will receive £1,042 (£312 bonus and £730 study payment) on completion of the study provided you comply fully with all the study requirements.

Get in touch
Call our team for more information: +44 (0) 20 7042 5800 (opt 1)
We are open weekdays 9am-5pm
or email us: volunteer@richmondpharmacology.com

Ref: E01 MUN_May 2018 (email_website_advert text)

The contents of this page have been approved by an ethics committee. Any response to this advertisement will be recorded. Your response will not place you under any obligation to participate in this trial.

You may be required to remain resident in the unit until resolution of any safety issues, after which you will be discharged from the unit.

Register your interest in this clinical trial